STP938 (novel investigational agent for Essential Thrombocythemia)
Current understanding
To be populated as evidence accumulates.
Evidence log
- 2026-01-28 — A Phase 1 Study to Assess STP938 as a Monotherapy in Adults With High Risk Essential Thrombocythaemia: Phase 1 monotherapy trial (trial-early) launched in adults with high-risk ET resistant to or intolerant of hydroxyurea, with daily dosing for up to 12 months and primary endpoints of safety/tolerability and platelet count control. (novelty: 4)
Open questions
Related
Contributing findings
A Phase 1 Study to Assess STP938 as a Monotherapy in Adults With High Risk Essential Thrombocythaemia
28-jan-2026
novelty 4
per-area 4
introduces